Compare RR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DTIL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 583.6M | 128.8M |
| IPO Year | 2023 | 2019 |
| Metric | RR | DTIL |
|---|---|---|
| Price | $2.30 | $5.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $60.00 |
| AVG Volume (30 Days) | ★ 9.7M | 180.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $5,045,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | $34.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.69 | $3.53 |
| 52 Week High | $7.43 | $8.82 |
| Indicator | RR | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 36.87 | 73.04 |
| Support Level | $1.83 | $4.50 |
| Resistance Level | $2.33 | $5.80 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | 0.02 | 0.16 |
| Stochastic Oscillator | 7.62 | 79.86 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.